Pharmacyte Biotech Inc (PMCB) 0.0570 $PMCB
PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu Jul 14, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes.
Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 90.39 (-0.61), MSFT: 53.70 (-0.04)
PharmaCyte Biotech to Hold Shareholder Call
GlobeNewswire - Mon Jul 11, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chief Executive Officer, Kenneth L. Waggoner, will conduct a shareholder conference call at 4:30 p.m. EDT on Thursday, July 28, 2016.
PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer
Marketwire Canada - Thu Jul 07, 8:03AM CDT
NEW YORK, NY--(Marketwired - July 07, 2016) - PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, is being used in treatments for both cancer and diabetes. For diabetes, the company's therapy, which is made up of pinhead-sized, porous capsules filled with insulin producing cells, will create an "artificial pancreas" for type 1 diabetics and insulin-dependent type 2 diabetics that no longer produce their own insulin. Meanwhile, for cancer, the company's therapy is made up of those same pinhead-sized, porous capsules; however, for advanced pancreatic cancer, they're filled with genetically modified cells that act as a type of "artificial liver."
Cannabis Attracting Big Business Operators as Multi-Billion Dollar Cannabis/Marijuana Industry Continues to Swell
PR Newswire - Wed Jul 06, 7:30AM CDT
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
XXII: 0.86 (unch), INSY: 14.98 (+0.22)
PharmaCyte's Research on Medical Uses of Cannabinoids Supported by Recent Scientific Article
GlobeNewswire - Tue Jul 05, 8:40AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that a recently published scientific article supports PharmaCyte's ongoing research efforts that concern medical uses for constituents of Cannabis known as cannabinoids. The article titled "Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids" was published in the journal, Aging and Mechanisms of Disease and appeared online on June 23, 2016. The article can be viewed in its entirety at http://www.nature.com/articles/npjamd201612
PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media.
PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.
PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research."
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.
PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.
PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016.
PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology.
PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
JNJ: 123.00 (-0.18)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.
PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu Jul 14, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes. Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 90.39 (-0.61), MSFT: 53.70 (-0.04)
PharmaCyte Biotech to Hold Shareholder Call
GlobeNewswire - Mon Jul 11, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chief Executive Officer, Kenneth L. Waggoner, will conduct a shareholder conference call at 4:30 p.m. EDT on Thursday, July 28, 2016. PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer
Marketwire Canada - Thu Jul 07, 8:03AM CDT
NEW YORK, NY--(Marketwired - July 07, 2016) - PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, is being used in treatments for both cancer and diabetes. For diabetes, the company's therapy, which is made up of pinhead-sized, porous capsules filled with insulin producing cells, will create an "artificial pancreas" for type 1 diabetics and insulin-dependent type 2 diabetics that no longer produce their own insulin. Meanwhile, for cancer, the company's therapy is made up of those same pinhead-sized, porous capsules; however, for advanced pancreatic cancer, they're filled with genetically modified cells that act as a type of "artificial liver."
Cannabis Attracting Big Business Operators as Multi-Billion Dollar Cannabis/Marijuana Industry Continues to Swell
PR Newswire - Wed Jul 06, 7:30AM CDT
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
XXII: 0.86 (unch), INSY: 14.98 (+0.22)
PharmaCyte's Research on Medical Uses of Cannabinoids Supported by Recent Scientific Article
GlobeNewswire - Tue Jul 05, 8:40AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that a recently published scientific article supports PharmaCyte's ongoing research efforts that concern medical uses for constituents of Cannabis known as cannabinoids. The article titled "Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids" was published in the journal, Aging and Mechanisms of Disease and appeared online on June 23, 2016. The article can be viewed in its entirety at http://www.nature.com/articles/npjamd201612 PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media. PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016. PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research." OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb. PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016. PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology. PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor. JNJ: 123.00 (-0.18)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance. 
